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  This EOLIC study on End-Of-Life Information and Communication was conducted in collaboration 
with a consortium of physicians who all recruited advanced lung cancer patients for inclusion in this study:, Dirk 
Ommeslag, Roger Devogelaere, Jan Van Meerbeeck, Jan Lamont, Anneke Lefebure, Lut Van Moorter, Elinck 
Willy, Annelies Janssens, Emmanuel Potvin, Alix Debrock, Dirk Verresen, Els De Droogh, Christophe 
Pollefliet, Karim Vermaelen and Elke van Schoote.  
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Abstract 
 
Purpose: Objective is to explore changes over time in the information and participation preferences of newly 
diagnosed stage IIIb/IV non-small-cell lung cancer patients.  
Methods: Patients were recruited by physicians in 13 hospitals and interviewed every two months until the 
fourth and every four months until the sixth interview. 
Results: Sixty seven patients were interviewed 3 times. Over a period of four months from diagnosis, half of 
patients changed their information preferences for palliative care and end-of-life decisions with a possible or 
certain life-shortening effect (ELDs, e.g. non-treatment decisions)  in both directions, from not wanting to 
wanting the information, but also - and as much - from wanting to no longer wanting it. The latter were more 
likely to be in a better physical condition. Preferences for participation in medical decision-making also changed: 
50% to 78%, depending on the type of decision (general, treatment, transfer or ELD), changed their preference 
towards wanting more or less participation. Pain seemed to be a trigger for patients wanting more involvement, 
which contrasts with studies suggesting that patients who are more ill tend to give up more control. 
Conclusions: Doctors should regularly ask their advanced lung cancer patients how much information and 
participation they want, because preferences do change in unexpected ways. 
 
Key words: Non-Small-Cell Lung; Patient participation; Medical decision-making; Information preferences; 
Palliative care; End-of-life decisions 
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Introduction  
 
There is a broad consensus that in physician-patient communication, for both ethical and clinical reasons, 
providing information to patients about their disease and treatment options and involving them in medical 
decision-making are important tasks [1-4]. However, especially in a serious illness with limited life expectancy 
such as advanced cancer, some patients may be reluctant to be fully informed or involved [5, 6]. Therefore, 
various authors have suggested that physicians have to be flexible and adjust their communication and decision-
making behavior to the specific preferences of the individual patient [7, 8]. 
 
There are several studies on the preferences of cancer patients for information and for participation in medical-
decision-making [9-13]. However, these are mostly cross-sectional and little is known about whether and in what 
direction the preferences of cancer patients change over time throughout the illness trajectory nor about the 
mechanisms of such changes. Insight into change of preferences over time could help physicians to adjust their 
communication, optimize the patient-physician relationship and possibly promote patient well-being.  
 
One study compared the information and participation preferences of cancer patients before and after a 
consultation with the physician and before a second consultation [14]. It was found that general preferences were 
stable in the short term, while in the long term they were not. Situational factors were important: patients who 
attended for a routine follow up were more likely to move towards preferring more involvement in decision-
making than were those whose condition had worsened.  
 
The aim of this study was to examine changes over time in information and participation preferences in 
advanced lung cancer patients. Information preferences were examined with regard to diagnosis, chances of cure, 
life expectancy, palliative care and end-of-life decisions with a possible or certain life-shortening effect (ELDs).  
In Belgium, palliative care is defined and organized in line with the definition of palliative care of the World 
Health Organization (WHO) [15]. This definition states that “palliative care is an approach that improves the 
quality of life of patients and their families facing the problem associated with life-threatening illness, through 
the prevention and relief of suffering” [16]. The WHO also stresses that palliative care is applicable early in the 
course of the illness in conjunction with other therapies. With the term ELDs, we refer to a specific group of 
end-of-life decisions that regularly have been studied in Belgium and other European countries and have a 
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possible or certain life-shortening effect [17, 18]. These ELDs are categorized in: withholding or withdrawing 
life-sustaining treatments, intensified alleviation of symptoms with a possible life-shortening effect, and 
administration of lethal drugs with the explicit intention of shortening a patient‟s life (euthanasia, physician 
assisted suicide or ending life without the patient‟s explicit request). With regard to the participation preferences 
we examined medical decisions in general, treatment decisions, health-care-setting transfer decisions and ELDs 
as well. Lung cancer patients were studied because of the high incidence of this disease and the lack of studies 
on information and participation preferences in this population [19, 20]. 
The research questions of this study were: 
1: Do preferences of advanced lung cancer patients concerning information and participation in medical 
decision-making change over time? 
2: What are the characteristics of patients with stable versus evolving preferences? 
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Methods 
 
Pulmonologists and oncologists of 3 university and 10 general hospitals in Flanders, Belgium, recruited 
consecutive patients with stage IIIb or IV non-small-cell lung cancer over one year. Patients had to be Dutch-
speaking and physically and psychologically able to participate in the study. Trained interviewers (psychologists, 
nurses...) interviewed the patients every two months until the fourth and every four months until the sixth 
interview.  
The recruitment period lasted from February 2007 to February 2008 (12 months), and the last interview took 
place in May 2009.  
 
Measures 
 
The patient interview consisted of several question lists and scales. Information preferences were assessed via 
seven items, first information preference in general and further with regard to six specific medical information 
topics: diagnosis, chances of cure, life expectancy, treatment options, palliative care and end-of-life decisions 
with a possible or certain life-shortening effect (ELDs). Palliative care was defined broadly to the patients as 
„comfort care, for patients who cannot be cured‟, in correspondence with the WHO definition of palliative care.  
ELDs were defined as „non-resuscitation orders, options to accelerate the end of life, and options to forgo or 
withdraw life-prolonging treatments‟. The preferences were presented in the form of statements which patients 
had to rate on a 6-point Likert scale (from totally disagree to totally agree).The question lists were based on 
existing questionnaires for cancer patients with confirmed validity, reliability, responsiveness and burden, and on 
data from qualitative research into terminally ill patients [21, 22]. 
 
Participation preferences were measured using an adaptation of the Control Preference Scale, which is frequently 
used in cancer studies [12, 23]. Patients were asked the question “Who do you want to take such decisions?” and 
had to choose one of five possible responses: 1) the doctor on the basis of his/her knowledge, 2) the doctor, but 
strongly taking my opinion into account, 3) myself and the doctor together on an equal basis, 4) myself, but strongly 
taking the doctor‟s opinion into account and 5) myself, on the basis of the information I have or receive. The first two 
statements denote a preference for primary doctor control over decision-making: doctor control without (1) and with 
patient input (2). The third statement (3) represents a preference for shared control with the physician and the last two 
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statements a preference for primary patient control: patient control with (4) and without (5) doctor input. Patients 
were given the adapted Control Preference Scale in relation to four situations: 1) medical decisions in general, 2) 
treatment decisions, 3) transfer decisions, i.e. decisions  concerning transfers between health-care-settings (home, 
hospital, nursing home, ,...) and 4) ELDs. We asked patients to consider decision situations that had actually taken 
place in the two months before the interview.  
 
To measure quality of life, the EORTC QLQ-C15-PAL was used [24, 25]. The EORTC QLQ-C15-PAL consists 
of 15 items and incorporates 4 multi-item and 6 single item-scales that measure different aspects of quality of life . 
The multi-item scales measure physical functioning, emotional functioning, fatigue and pain. The single item-scales 
measure additional symptoms and global quality of life. Socio-demographic and clinical patient characteristics were 
recorded by the physician at inclusion of the patient in the study. The clinical characteristic of co-morbidity was 
measured with the Charlson Index [26]. In Charlson‟s Co-morbidity Index, the physician has to mark the 
concomitant diseases the patient suffer from according to a list of 19 diseases that all bear a relative risk of death 
larger than 1.2. If no disease is marked, a score of 0 is given. Higher scores mean that the patient suffers from one or 
more concomitant diseases. 
 
Ethics 
 
The protocol of the study was approved by the Ethical Review Board of the University Hospital of the Vrije 
Universiteit Brussel and of all participating hospitals.  
 
Statistical analysis 
 
Firstly, we explored changes in the average score (population level) on the information and participation 
preference-items over the interview moments. We used the explorative LOWESS regression technique with the 
ratings on the preference items as dependent variable, and time (in days since inclusion) as independent variable 
[27]. The LOWESS technique was chosen because it allows use of all data collected, despite the variable number 
of interviews per patient (ranging from 1 to 6 interviews). A disadvantage of the technique is that it is only 
explorative and does not allow for statistical significance statements. 
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Secondly, even if there are no changes in the average ratings over time (i.e. no temporal change at the population 
level), individual patients might still change towards wanting more or less information and participation over 
time (temporal change at the individual level). To examine these changes and the predictors of these changes in- 
depth, we selected the patients who had been interviewed three times and gave the percentages of patients who 
changed their preference at the second and/or third interview, compared with the first. For this purpose, the 
information preference items were dichotomized into wanting versus not wanting information and the 
participation preference items were categorized into wanting doctor, shared or patient control. 
 
The predictors of change and no change in preferences were explored by testing patient characteristics for 
significant association with change/no change (from wanting to not wanting information and vice versa, and 
between wanting doctor, shared or patient control over decision-making), using the Mann Whitney U test and the 
Fisher‟s Exact Test. 
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Results 
 
One hundred and ninety six patients were reported to meet the inclusion criteria, of which 152 were included. Of 
the included patients, 19 could not be enrolled because they were too ill or had died before the first interview, 
three could not be contacted, and two interviews had too many missing values. In total, 128 patients were 
interviewed at least once (68% participation rate). Sixty seven of the 128 patients were interviewed three times.  
 
Figure 1 shows the number of participants and those lost to follow-up over the course of the study. The median 
duration of follow-up was 15 months, counting from the first interview (mean of 14.8 months) as well as from 
inclusion (mean of 15.2 months).   
 
Patient characteristics (Table 1)  
 
The mean age of the 128 participants was 64 years (range 41-86), 80% were male and 77% had a partner. At 
inclusion, 71% were being treated with life-prolonging intent, 21% with palliative intent and 7% with curative 
intent. Eighty-two per cent were receiving chemotherapy, sometimes in combination with radiotherapy. Eighty 
seven percent had a good performance status at inclusion and half were suffering from co-morbidity according to 
the Charlson Index. The mean estimated life expectancy since inclusion in the study was 10.6 months. There 
were no significant differences between the inclusion sample and the 67 patients who completed three 
interviews.  
 
Changes in information and participation preferences of the „average advanced lung cancer patient‟ over six 
interviews  
 
At the population level, advanced lung cancer patients‟ preferences for information in general (without 
specifying the topic), and for information about diagnosis, prognosis and treatment options were high shortly 
after inclusion and remained so over time, until 15 months after inclusion. The preferences for information about 
palliative care and end-of-life decisions with a possible or certain life-shortening effect (ELDs) were lower, but 
also did not change over time (Figure 2). 
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The preferences for participation in medical decision-making hardly changed over time until approximately one 
year after inclusion, at which time preferences for participation in all medical decisions (general, treatment, 
transfer and end-of life decisions) began to increase gradually (Figure 3).  
 
Changes in preferences of individual patients over three interviews (N=67) 
 
Information preferences 
 
Practically all patients wanted information in general (98%), about diagnosis (100%), treatment options (100%), 
chances of cure (98%) and life expectancy (92%) at t1, shortly after diagnosis of NSCLC IIIb or IV. Almost all 
still wanted this information at t2 and t3, two and four months later, 97% with regard to information in general, 
100% with regard to diagnosis, 92% with regard to treatment options, 97% with regard to chances of cure and 
90% with regard to life expectancy.  
 
As for the topics of palliative care and ELDs, respectively 64% and 52% wanted this information at t1, and 36% 
and 48% did not. Of the patients who did not want this information at t1, one fourth changed their minds towards 
wanting it at t2 or t3 (26% and 23%) and a very few fluctuated (not wanting – wanting – not wanting 
information, 0% and 6%). Of the patients who wanted this information at t1, 39% and 26% respectively changed 
towards not wanting it and some patients fluctuated (15% and 18%).  
 
Participation preferences (Table 2) 
 
For general medical decisions and treatment and transfer decisions, most patients (51% to 62%), wanted doctor 
control at t1 rather than shared or personal control; for ELDs most preferred personal control (49%) rather than 
shared (39%) or doctor control (12%). All preferences, whether for doctor control, shared control or patient 
control, in all studied medical decisions, were unstable, with half or more patients changing their preference 
towards wanting more or less control at t2 or t3. There was one exception: most patients (76%) who wanted 
doctor control in treatment decisions at t1 had not changed this preference at t2 or t3. Overall, 50% of patients 
changed their participation preference in treatment decisions at t2 or t3 compared with t1; 59% did this for 
ELDs, 62% for medical decisions in general and 77% for transfer decisions. 
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Characteristics associated with changes in preferences (Table 3) 
 
Compared with older patients and those with a partner, younger patients and those without a partner were more 
likely to change their preference for information about palliative care over time from not wanting to wanting 
information. Religion was also related to change in preferences: non-religious patients were more likely to state 
they no longer wanted information about palliative care, and to want more participation (i.e. to change from 
doctor to shared or patient control) in treatment decisions.  
 
A clinical patient characteristic that played an important role in changing preferences was the physical condition 
of the patient: those with a worse physical condition were more likely to continue over time to want information 
about palliative care and ELDs, and those with more pain were inclined to want more participation over time in 
decision-making, at least for medical decisions in general and for transfer decisions. A less than good 
performance status at inclusion was also related to wanting more participation over time in medical decisions in 
general. 
 
We checked whether those who changed from wanting to not wanting information about palliative care and 
ELDs did so because the information had been provided by the physician in the meantime. We found that of 
these patients only 12% (palliative care) and 11% (ELDs) reported having been informed during the interview 
period. For comparison, of those who consistently wanted information, 53% and 47% had received it, and of 
those who consistently did not want it, 13% and 4% had. 
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Discussion  
 
This is the first longitudinal study of information and participation preferences in a cohort of newly diagnosed 
advanced cancer patients. Information preferences could be measured with regard to diagnosis, chances of cure, 
life expectancy, palliative care and end-of-life decisions with a possible or certain life-shortening effect (ELDs). 
Participation preferences could be measured with regard to medical decisions in general, treatment decisions, 
transfer decisions and end-of-life decisions. 
 
Although the patients as a group did not change much over time towards wanting more or less information or 
participation, individual patients did. The preferences for information about diagnosis, prognosis and treatment 
options were stable: almost all patients wanted this information shortly after diagnosis and continued to want it 
two and four months later. In contrast, the preferences for information about palliative care and ELDs were 
unstable: of the patients who did not want this information at the onset, one fourth changed towards wanting it 
after four months, and of those who did want it, 39% (palliative care) and one fourth (ELDs) changed towards 
not wanting it. Patients in a worse physical condition were more likely to continue to want information about 
these topics. The preferences for participation in medical decision-making were also unstable: 50% to 78%, 
depending on the type of decision (general, treatment, transfer or end-of-life), changed their preference towards 
wanting more or less participation over four months. Patients who had more pain were more likely to change 
towards wanting more participation, at least in medical decisions in general and in transfer decisions.  
 
Strengths of the study were the attempt to have a representative sample of patients by recruiting a cohort of 
consecutive patients during one year in 13 hospitals, the limited drop-out throughout the study period due to 
reasons other than death or being too ill (although the latter reason may have concealed loss of interest in the 
study), and the measurement of aspects of quality of life (physical and emotional functioning, pain and fatigue) 
along with the preferences of the patients as possible predictors of the preferences.  
A limitation of the study was that we only studied the 67 patients that we interviewed three times and not all 128 
included patients, and therefore caution is needed in generalizing the findings: most patients who dropped-out 
before the third interview were too ill or had died. Another limitation was that we explored the association 
between change in preferences and several patient characteristics, enhancing the likelihood of finding 
 12 
associations that are not existent on a population level. A final limitation concerned the possible varying 
interpretations by the patients of  the precise content of the information topics despite of specific definitions.  
 
An important finding of the study was that almost all advanced lung cancer patients wanted and kept on wanting 
information about diagnosis, treatment options, chances of cure and life expectancy. So, even in those patients 
who received information about these topics, the preference for information persisted, suggesting that physicians 
would do well to update their patients regularly. This is in conformity with other study findings showing that 
advanced cancer patients want information provision to be an ongoing process where the physician continually 
checks their understanding and goals, particularly as the situation may change during the course of the illness 
[28]. 
 
In contrast, the preferences for information about palliative care and ELDs were more variable and unstable. Of 
the substantial minority of patients who initially did not want this information, one fourth later did. Of the 
majority who originally did want it, about half changed their minds – sometimes temporarily – to not wanting it. 
Thus, it seems that even after a longer period of time (four months after diagnosis), there remain many patients 
who are not open to information about palliative and end-of-life care. This might compromise their preparedness 
when they eventually reach the terminal phase and thus might affect the quality of their end-of-life care.   
 
Two comments have to be made. Firstly, it could be that patients change from wanting to not wanting 
information about palliative care and ELDs because they receive the information in the meantime. However, this 
explanation is inadequate: only a fraction (one tenth) did actually receive information between interviews. 
Rather, we observed that a patient‟s physical condition played a role: patients whose pain level and level of 
physical functioning were worse kept on wanting information about palliative care, while patients with better 
functioning and  less pain did not. It seems that pain and a lower level of physical functioning  worsens quality 
of life and leads patients to want to be more in control in the hope of achieving more pain and symptom control. 
The relationship between the physical condition and information preferences also suggests that patients who 
change towards not wanting information might want information again later on, when their condition worsens. 
This carries the risk however that, for those who deteriorate rapidly, there will not be time to become sufficiently 
informed and prepared with regard to palliative and end-of-life care. The fact that so few physicians gave 
information regarding palliative care and ELDs during the first few months is possibly also important in this 
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context as it could lead a patient to think that the issues are not relevant precisely because the physician has not 
raised them. Secondly, those patients who never wanted information about palliative care were more likely to be 
older and to have a partner. It might be that some of them rely more on their family or partner, in which case the 
physician might want to consider addressing family members or partners about palliative care and end of life 
issues in order to ensure good quality care according to the patient‟s preferences [29]. 
 
Half of patients changed their preference regarding participation in treatment decisions over the first four months 
of the disease, around 60% for medical decisions in general and for end-of-life decisions and 77% for transfer 
decisions. These relatively high percentages make it necessary for the physician to check a patient‟s preferences 
every time a decision is to be made.  
 
Of interest is that patients who - over the first four months of their disease - had more pain were more likely to 
change over time from doctor control towards shared or patient control, at least in medical decisions in general 
and in transfer decisions. Pain seems to be a trigger for patients to want more involvement, which somewhat 
contrasts with studies suggesting that patients who are more ill tend to give up more control [14, 30].
 
 
 
To conclude, several recommendations can be made for clinical practice. Firstly, this study corroborates findings 
of other studies that physicians generally provide information about palliative care and ELDs far less often than 
patients want it. This speaks to the importance of physician addressing these topics. Secondly, the preferences of 
advanced lung cancer patients for information about palliative care and ELDs and for participation in medical 
decision-making are relatively unstable over time. This means that in order to take preferences into account in 
daily clinical practice, their immediate preferences need to be considered.  In this context it is important that 
physicians talk to their patients about their preferences for information and participation in decision-making and 
inform them that change in preferences over time is possible and always can be communicated.  
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FIGURES 
 
Figure 1 Participation of NSCLC IIIb or IV patients in study (N=128) 
 
Figure 2 Information preferences of the studied patients over time (Lowess curve) 
Figure 3 Participation preferences of the studied patients over time (Lowess curve) 
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Table 1  Characteristics at inclusion of the advanced lung cancer patients studied  
 
 All patients 
 
N=128 
Patients with 3 
consecutive 
interviews 
N=67 
P-value* 
 Mean (SD) Mean (SD)  
Age 64.4 (9.7) 64.2 (9.8) 0.884 
 N (%) N (%)  
Sex  Male  102 (79.7) 53 (79.1) 1.000 
Female 26 (20.3) 14 (20.9) 
Partner Yes 98 (76.6) 53 (79.1) 0.722 
No 30 (23.4) 14 (20.9) 
Living situation Home alone 31 (24.2) 17 (25.4) 0.863 
Home with others 97 (75.8) 50 (74.6) 
Education  Primary school 24 (18.8) 12 (17.9) 0.699 
Lower secondary 42 (32.8) 17 (25.4) 
Higher secondary 40 (31.2) 25 (37.3) 
Higher education 22 (17.2) 13 (19.4) 
Religion  Religious 93 (72.7) 49 (71.0) 1.000 
Not religious 35 (27.3) 18 (26.1) 
Treating hospital University  59 (46.1) 29 (43.3) 0.763 
General 69 (53.9) 38 (56.7) 
Treatment aim Cure 9 (7.0) 7 (10.4) 0.805 
Life prolongation 91 (71.1) 47 (70.1) 
Palliation 27 (21.1) 13 (19.4) 
Other (no treatment) 1 (0.8) 0(0.0) 
Chemotherapy Yes 105 (82.0) 53 (79.1) 0.701 
No 23 (18.0) 14 (20.9) 
Radiotherapy Yes 41 (32.0) 23 (34.3) 0.751 
No 87 (68.0) 44 (65.7) 
Contact with GP
a  
Once a week or more 11 (8.6) 3 (4.5) 0.737 
Once every 2 weeks 17 (13.3) 6 (9.0) 
Once every month 59 (46.1) 33 (49.3) 
Less 41 (32.0) 25 (37.3) 
Co-morbidity
b 
0 65 (50.8) 32 (47.8) 0.897 
1-2 53 (41.4) 29 (43.3) 
3-4 10 (7.8) 6 (9.0) 
Performance status
c 
0 31 (24.2) 22 (32.8) 0.313 
1 81 (63.3) 42 (62.7) 
2 11 (8.6) 2 (3.0) 
3 3 (2.3) 0(0.0) 
4 2 (1.6) 1 (1.5) 
 Mean (SD) Mean (SD)  
Life expectancy (in months)
d   
10.6 (4.5) 11.8 (4.6) 0.083 
* P-value of significance testing using Man-Whitney U or Fisher‟s Exact Test. 
a Three patients (in n=128) and two patients (in n=67) reported that they didn‟t have a GP. They were included 
in the category „Less‟. 
b
 Co-morbidity score of Charlson Index. 
c 
Performance status according to ECOG: Eastern Cooperative Oncology Group, ranging from 0 = fully active 
to 4 = completely disabled. 
d
 Estimated by treating physician. 
*Significance testing with Mann-Whitney U or Fisher‟s exact test. 
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Table 2 Change in preferences of advanced lung cancer patients for  participation in medical decisions in general, treatment, transfer and end-of-life 
decisions during the first four months after diagnosis of NSCLC IIIb or IV (N=67) 
 
 N(%) of patients who changed and didn’t change their participation preference at 
t2 and t3, compared to t1 
 
Medical decisions 
in general 
Treatment 
decisions 
Transfer decisions End-of-life 
decisions 
     Of patients who wanted doctor control at t1 N=34 (100) N=41(100) N=37 (100) N=7 (100) 
          No change at t2 and t3 17 (50.0) 31 (75.6) 11 (29.7) 2 (28.6) 
          Evolution towards wanting shared or patient control 14 (41.2) 8 (19.5) 20 (54.1) 4 (57.1) 
          Fluctuation: doctor control/ … /doctor control 3 (8.8) 2 (4.9) 6 (16.2) 1 (14.3) 
     Of patients who wanted shared control at t1 N=25 (100) N=15 (100) N=16 (100) N=23 (100) 
          No change at t2 and t3 8 (32.0) 1(6.7) 1 (6.3) 7 (30.4) 
          Evolution towards wanting patient or doctor control 12 (48.0) 8 (53.3) 11 (68.7) 9 (39.1) 
          - Patient control 3 (12.0) 0 (0.0) 4(25.0) 5 (21.7) 
          - Doctor control 9 (36.0) 8 (53.3) 7(43.7) 4 (17.4) 
          Fluctuation: shared control/… /shared control; 
          shared/doctor/ patient and shared/patient/doctor 
5 (20.0) 6 (40.0) 4 (25.0) 7 (30.4) 
     Of patients who wanted personal control at t1 N=7 (100) N=10 (100) N=13 (100) N=29 (100) 
          No change at t2 and t3 0 (0.0) 1(10.0) 3 (23.1) 15 (51.7) 
          Evolution towards wanting shared or doctor control 6 (85.7) 6(60.0) 5 (38.5) 10 (34.5) 
          Fluctuation: patient control/…/patient control 1 (14.3) 3 (30.0) 5 (38.5) 4 (13.7) 
Of all patients (Total) N=66 (100) N=66 (100) N=66 (100) N=59 (100) 
     No change at t2 and t3 25 (37.9) 33 (50.0) 15 (22.7) 24 (40.7) 
     Evolution 32 (48.5) 22 (33.3) 36 (54.5) 23 (39.0) 
     Fluctuation 9 (13.6) 11 (16.7) 15 (22.7) 12 (20.3) 
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Table 3 Characteristics of patients who changed and did not change their preferences for information about palliative care and ELDs and for 
participation in medical decision-making 
 
 Change in preferences over time (at t2 or t3)  Mean or % of patients P* 
 Change No change 
Age (in years) Change to wanting information about palliative care  Mean: 60.3 Mean: 71.3 0.015 
  (n=6) (n=17)  
Having no partner  Change to wanting information about palliative care 50.0% 5.9% 0.040 
(versus having a partner)  (n=6) (n=17)  
Not religious  Change to not wanting information about palliative care 87.5% 47.7% 0.030 
(versus religious)  (n=16) (n=19)  
 Change to wanting more involvement in treatment decisions 62.5% 19.4% 0.028 
  (n=8) (n=31)  
Average physical functioning  Change to not wanting information about palliative care Mean: 86.1 Mean: 70.6 0.003 
over t1, t2 and t3 
(high score: healthy level) 
 (n=16) (n=19)  
Change to not wanting information about ELDs Mean: 86.8 Mean: 73.5 0.019 
 (n=9) (n=19)  
Average pain over t1, t2, t3  Change to not wanting information about palliative care Mean: 21.9 Mean: 37.7 0.029 
(low score: healthy level)  (n=16) (n=19)  
Change to wanting more involvement in medical decisions in  Mean: 31.7 Mean: 14.4 0.040 
general (n=14) (n=17)  
 Change to wanting more involvement in transfer decisions Mean: 24.4 Mean: 7.1 0.021 
  (n=20) (n=11)  
Average fatigue over t1, t2, t3 Change to not wanting information about palliative care Mean: 28.4  Mean: 49.4 0.007 
(low score: healthy level)  (n=16) (n=19)  
Co-morbidity at inclusion  Change to not wanting information about ELDs 22.2% 68.4% 0.025 
(versus no Co-morbidity)
a
  (n=9) (n=19)  
Performance status at inclusion: 
active  (versus less active)
 b
 
Change to wanting more involvement in medical decisions in  14.3% 58.8% 0.024 
general (n=14) (n=17)  
* P-value of significance testing (P<0.05) using Man-Whitney U or Fisher‟s Exact Test. Patient characteristics that were tested for a significant 
association with change and no change in preferences  were: 1) socio-demographic and clinical characteristics measured at inclusion (age, sex, 
educational level, having a partner, religion, treatment aim, performance status, comorbidity) and 2) quality of life variables measured at each 
interview averaged over the three interviews (EORTC QLQ-C15-PAL multiple item-scales: physical functioning, emotional functioning, fatigue and 
pain). 
a
 Co-morbidity score of 1-4 (co-morbidity) versus 0 (no co-morbidity), measured by Charlson Index. 
b
 ECOG score of 0 (active) versus 1-4 (less active), measured according to ECOG (Eastern Cooperative Oncology Group). 
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